Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Response rates of extra-nodal diffuse large B cell lymphoma to anti-CD19-CAR T cells: A real word retrospective multicenter study.
Beyar Katz O, Perry C, Grisariu-Greenzaid S, Yehudai-Ofir D, Luttwak E, Avni B, Zuckerman T, Sdayoor I, Stepensky P, Ringelstein-Harlev S, Bar-On Y, Libster D, Sharvit L, Amit O, Greenbaum U, Gold R, Herishanu Y, Benyamini N, Avivi I, Ram R. Beyar Katz O, et al. Eur J Haematol. 2023 Jul;111(1):63-71. doi: 10.1111/ejh.13968. Epub 2023 Apr 10. Eur J Haematol. 2023. PMID: 36964939
The future of medicine: a students' perspective.
Bodner O, Nashashibi J, Katz OB, Shechter D. Bodner O, et al. Among authors: katz ob. Lancet. 2016 Jan 23;387(10016):340. doi: 10.1016/S0140-6736(16)00112-4. Lancet. 2016. PMID: 26842455 No abstract available.
Eosinophilic pleocytosis in the cerebrospinal fluid following CAR-T cell therapy for CNS lymphoma: A case for warning?
Abu Ata M, Henig I, Yehudai-Ofir D, Tzoran I, Ringelstein-Harlev S, Inbar T, Slouzkey I, Karmona Fintuch M, Stern A, Stanevsky O, Weiler-Sagie M, Zohar Y, Livneh I, Merhav G, Eran A, Zuckerman T, Katz OB. Abu Ata M, et al. Among authors: katz ob. Acta Haematol. 2024 May 23. doi: 10.1159/000539354. Online ahead of print. Acta Haematol. 2024. PMID: 38781944
Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysis.
Avivi I, Perry C, Segman Y, Amit O, Bar-On Y, Katz OB, Gold R, Ribakovsky E, Avigdor A, Vainstein V, Goldschmidt N, Ringelstein-Harlev S, Horowitz NA, Gutwein O, Gurion R, Itchaki G, Abadi U, Nemets A, Sofer O, Vezker M, Tadmor T, Dally N, Filanovsky K, Leiba M, Sarid N, Benyamini N, Luttwak E, Herishanu Y, Ram R. Avivi I, et al. Among authors: katz ob. Ann Hematol. 2022 Apr;101(4):755-762. doi: 10.1007/s00277-021-04749-9. Epub 2022 Jan 27. Ann Hematol. 2022. PMID: 35083525